| Catalog No. | Size | Price (USD) |
| 11221-MM08-20 | 20 µL | $88.87 |
| 11221-MM08-100 | 100 µL | $251.64 |
General Information
| Product name | Anti-Apolipoprotein H Antibody, Mouse Monoclonal |
| Validated applications | ELISA(Det) (FAQ Protocol) |
| Species reactivity | Reacts with: Human |
| Specificity | Human Apolipoprotein H |
| Immunogen | Recombinant Human Apolipoprotein H Protein (Catalog#11221-H08H) |
| Preparation | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human Apolipoprotein H (rh Apolipoprotein H; Catalog#11221-H08H; NP_000033.2; Met1-Cys345). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
| Source | Monoclonal Mouse IgG1 Clone #08 |
| Purification | Protein A |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-B2G1 Antibody; Anti-B2GP1 Antibody; Anti-BG Antibody
Background Information
| Full Name | apolipoprotein H (beta-2-glycoprotein I) |
| Description | Apolipoprotein H (APOH), also known as Beta-2-glycoprotein 1, Activated protein C-binding protein, B2GPI, and B2G1, is a glycoprotein synthesized by liver cells and it is present in the blood associated with plasma lipoproteins. It is an essential cofactor for the binding of certain antiphospholipid antibodies (APA) to anionic phospholipid. APOH binds to various kinds of negatively charged substances such as heparin, phospholipids, and dextran sulfate. APOH may prevent activation of the intrinsic blood coagulation cascade by binding to phospholipids on the surface of damaged cells. APOH appears to completely inhibit serotonin release by the platelets and prevents subsequent waves of the ADP-induced aggregation. The activity of APOH appears to involve the binding of agglutenating, negatively charged compounds, and inhibits agglutenation by the contact activation of the intrinsic blood coagulation pathway. APOH causes a reduction of the prothrombinase binding sites on platelets and reduces the activation caused by collagen when thrombin is present at physiological serum concentrations of APOH suggesting a regulatory role of APOH in coagulation. APOH plasma concentrations are strongly associated to metabolic syndrome alterations and vascular disease in type 2 diabetic and could be considered as a clinical marker of cardiovascular risk. APOH is found on several classes of lipoproteins, and is involved in the activation of lipoprotein lipase in lipid metabolism. This single-chain glycoprotein also has been implicated in several physiologic pathways including coagulation and the production of hypertension, which are related to the pathogenesis of primary cerebral hemorrhage (PICH). |
| References |
|
